{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T02:41:45Z","timestamp":1779244905885,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T00:00:00Z","timestamp":1536624000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00296-018-4156-4","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T02:34:37Z","timestamp":1536633277000},"page":"2279-2288","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["High burden of skin sclerosis is associated with severe organ involvement in patients with systemic sclerosis and systemic sclerosis overlap syndrome"],"prefix":"10.1007","volume":"38","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1839-1903","authenticated-orcid":false,"given":"Thapat","family":"Wannarong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5412-4055","authenticated-orcid":false,"given":"Chayawee","family":"Muangchan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,9,11]]},"reference":[{"key":"4156_CR1","first-page":"1281","volume":"22","author":"P Clements","year":"1995","unstructured":"Clements P, Lachenbruch P, Siebold J et al (1995) Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 22:1281\u20131285","journal-title":"J Rheumatol"},{"key":"4156_CR2","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1002\/1529-0131(200011)43:11<2437::AID-ANR10>3.0.CO;2-U","volume":"43","author":"VD Steen","year":"2000","unstructured":"Steen VD, Medsger TA Jr (2000) Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 43:2437\u20132444","journal-title":"Arthritis Rheum"},{"key":"4156_CR3","doi-asserted-by":"publisher","first-page":"2445","DOI":"10.1002\/1529-0131(200011)43:11<2445::AID-ANR11>3.0.CO;2-Q","volume":"43","author":"PJ Clements","year":"2000","unstructured":"Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B et al (2000) Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 43:2445\u20132454","journal-title":"Arthritis Rheum"},{"key":"4156_CR4","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1136\/annrheumdis-2015-207271","volume":"75","author":"EG Wirz","year":"2016","unstructured":"Wirz EG, Jaeger VK, Allanore Y, Riemekasten G, Hachulla E, Distler O et al (2016) Incidence and predictors of cutaneous manifestations during the early course of systemic sclerosis: a 10-year longitudinal study from the EUSTAR database. Ann Rheum Dis 75:1285\u20131292","journal-title":"Ann Rheum Dis"},{"key":"4156_CR5","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1136\/annrheumdis-2014-205295","volume":"75","author":"J Avouac","year":"2016","unstructured":"Avouac J, Walker UA, Hachulla E, Riemekasten G, Cuomo G, Carreira PE et al (2016) Joint and tendon involvement predict disease progression in systemic sclerosis: a EUSTAR prospective study. Ann Rheum Dis 75:103\u2013109","journal-title":"Ann Rheum Dis"},{"key":"4156_CR6","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1136\/annrheumdis-2014-205226","volume":"74","author":"B Maurer","year":"2015","unstructured":"Maurer B, Graf N, Michel BA, M\u00fcller-Ladner U, Czirj\u00e1k L, Denton CP et al (2015) Prediction of worsening of skin fibrosis in patients with diffuse cutaneous systemic sclerosis using the EUSTAR database. Ann Rheum Dis 74:1124\u20131131","journal-title":"Ann Rheum Dis"},{"key":"4156_CR7","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1002\/art.1780230510","volume":"23","author":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee","year":"1980","unstructured":"Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581\u2013590","journal-title":"Arthritis Rheum"},{"key":"4156_CR8","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1136\/annrheumdis-2013-204424","volume":"72","author":"F Hoogen Van den","year":"2013","unstructured":"Van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A et al (2013) 2013 classification criteria for systemic sclerosis: an American college of rheumatology\/European league against rheumatism collaborative initiative. Ann Rheum Dis 72:1747\u20131755","journal-title":"Ann Rheum Dis"},{"key":"4156_CR9","first-page":"202","volume":"15","author":"EC LeRoy","year":"1988","unstructured":"LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202\u2013205","journal-title":"J Rheumatol"},{"key":"4156_CR10","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/art.23501","volume":"58","author":"AE Postlethwaite","year":"2008","unstructured":"Postlethwaite AE, Wong WK, Clements P, Chatterjee S, Fessler BJ, Kang AH et al (2008) A multicenter, randomized, double-blind, placebo-controlled trial of oral type I collagen treatment in patients with diffuse cutaneous systemic sclerosis: I. oral type I collagen does not improve skin in all patients, but may improve skin in late-phase disease. Arthritis Rheum 58:1810\u20131822","journal-title":"Arthritis Rheum"},{"key":"4156_CR11","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1136\/ard.2006.062901","volume":"66","author":"UA Walker","year":"2007","unstructured":"Walker UA, Tyndall A, Czirj\u00e1k L, Denton C, Farge-Bancel D, Kowal-Bielecka O et al (2007) Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 66:754\u2013763","journal-title":"Ann Rheum Dis"},{"key":"4156_CR12","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.semarthrit.2011.10.004","volume":"41","author":"CP Sime\u00f3n-Aznar","year":"2012","unstructured":"Sime\u00f3n-Aznar CP, Fonollosa-Pl\u00e1 V, Tolosa-Vilella C, Espinosa-Garriga G, Ramos-Casals M, Campillo-Grau M et al (2012) Registry of the Spanish network for systemic sclerosis: clinical pattern according to cutaneous subsets and immunological status. Semin Arthritis Rheum 41:789\u2013800","journal-title":"Semin Arthritis Rheum"},{"key":"4156_CR13","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/art.22747","volume":"56","author":"A Perera","year":"2007","unstructured":"Perera A, Fertig N, Lucas M, Rodriguez-Reyna TS, Hu P, Steen VD et al (2007) Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody. Arthritis Rheum 56:2740\u20132746","journal-title":"Arthritis Rheum"},{"key":"4156_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1136\/ard.2009.127621","volume":"70","author":"RT Domsic","year":"2011","unstructured":"Domsic RT, Rodriguez-Reyna T, Lucas M, Fertig N, Medsger TA Jr (2011) Skin thickness progression rate: a predictor of mortality and early internal organ involvement in diffuse scleroderma. Ann Rheum Dis 70:104\u2013109","journal-title":"Ann Rheum Dis"},{"key":"4156_CR15","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/rheumatology\/ker333","volume":"51","author":"M Hasegawa","year":"2012","unstructured":"Hasegawa M, Asano Y, Endo H, Fujimoto M, Goto D, Ihn H et al (2012) Investigation of prognostic factors for skin sclerosis and lung function in Japanese patients with early systemic sclerosis: a multicenter prospective observational study. Rheumatology (Oxford) 51:129\u2013133","journal-title":"Rheumatology (Oxford)"},{"key":"4156_CR16","doi-asserted-by":"publisher","first-page":"217","DOI":"10.3109\/03009742.2013.868512","volume":"43","author":"M Jung","year":"2014","unstructured":"Jung M, Bonner A, Hudson M, Baron M, Pope JE, Canadian Scleroderma Research Group (CSRG) (2014) Myopathy is a poor prognostic feature in systemic sclerosis: results from the Canadian Scleroderma Research Group (CSRG) cohort. Scand J Rheumatol 43:217\u2013220","journal-title":"Scand J Rheumatol"},{"key":"4156_CR17","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1080\/07315724.2010.10719828","volume":"29","author":"M Baron","year":"2010","unstructured":"Baron M, Hudson M, Steele R, Canadian Scleroderma Research Group (CSRG) (2010) Is serum albumin a marker of malnutrition in chronic disease? The scleroderma paradigm. J Am Coll Nutr 29:144\u2013151","journal-title":"J Am Coll Nutr"},{"key":"4156_CR18","first-page":"122","volume":"31","author":"C Muangchant","year":"2013","unstructured":"Muangchant C, Pope JE (2013) The significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature review. Clin Exp Rheumatol 31:122\u2013134","journal-title":"Clin Exp Rheumatol"},{"key":"4156_CR19","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1517\/17425255.2015.1076391","volume":"11","author":"AY Gasparyan","year":"2015","unstructured":"Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD (2015) Colchicine as an anti-inflammatory and cardioprotective agent. Expert Opin Drug Metab Toxicol 11:1781\u20131794","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"4156_CR20","first-page":"705","volume":"6","author":"D Alarcon-Segovia","year":"1979","unstructured":"Alarcon-Segovia D, Ramos-Niembro F, Ibanez de Kasep G, Alcocer J, Tamayo RP (1979) Long-term evaluation of colchicine in the treatment of scleroderma. J Rheumatol 6:705\u2013712","journal-title":"J Rheumatol"},{"key":"4156_CR21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.170953","author":"S Alharbi","year":"2018","unstructured":"Alharbi S, Ahmad Z, Bookman AA, Touma Z, Sanchez-Cuerrero J, Mitsakakis N et al (2018) Epidemiology and survival of systemic sclerosis\u2014systemic lupus erythematosus overlap syndrome. J Rheumatol. \n                    https:\/\/doi.org\/10.3899\/jrheum.170953","journal-title":"J Rheumatol"},{"key":"4156_CR22","doi-asserted-by":"publisher","first-page":"2422","DOI":"10.1002\/art.22721","volume":"56","author":"L Shand","year":"2007","unstructured":"Shand L, Lunt M, Nihtyanova S, Hoseini M, Silman A, Black CM et al (2007) Relationship between change in skin score and disease outcome in diffuse cutaneous systemic sclerosis: application of a latent linear trajectory model. Arthritis Rheum 56:2422\u20132431","journal-title":"Arthritis Rheum"},{"key":"4156_CR23","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1093\/rheumatology\/ken179","volume":"47","author":"N Hunzelmann","year":"2008","unstructured":"Hunzelmann N, Genth E, Krieg T, Lehmacher W, Melchers I, Meurer M et al (2008) The registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvement. Rheumatology 47:1185\u20131192","journal-title":"Rheumatology"},{"key":"4156_CR24","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1136\/ard.2008.091348","volume":"68","author":"UA Walker","year":"2009","unstructured":"Walker UA, Tyndall A, Czirj\u00e1k L, Denton CP, Farge-Bancel D, Kowal-Bielecka O et al (2009) Geographical variation of disease manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials and Research (EUSTAR) group database. Ann Rheum Dis 68:856\u2013862","journal-title":"Ann Rheum Dis"},{"key":"4156_CR25","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1136\/annrheumdis-2013-204487","volume":"74","author":"P Moinzadeh","year":"2015","unstructured":"Moinzadeh P, Aberer E, Ahmadi-Simab K, Blank N, Distler JH, Fierlbeck G (2015) Disease progression in systemic sclerosis-overlap syndrome is significantly different from limited and diffuse cutaneous systemic sclerosis. Ann Rheum Dis 74:730\u2013737","journal-title":"Ann Rheum Dis"},{"key":"4156_CR26","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1111\/1756-185X.12884","volume":"19","author":"C Foocharoen","year":"2016","unstructured":"Foocharoen C, Netwijitpan S, Mahakkanukrauh A, Suwannaroj S, Nanagara R (2016) Clinical characteristics of scleroderma overlap syndromes: comparisons with pure scleroderma. Int J Rheum Dis 19:913\u2013923","journal-title":"Int J Rheum Dis"},{"key":"4156_CR27","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.3899\/jrheum.101248","volume":"38","author":"A Pakozdi","year":"2011","unstructured":"Pakozdi A, Nihtyanova S, Moinzadeh P, Ong VH, Black CM, Denton CP (2011) Clinical and serological hallmarks of systemic sclerosis overlap syndromes. J Rheumatol 38:2406\u20132409","journal-title":"J Rheumatol"},{"key":"4156_CR28","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s00296-006-0207-3","volume":"27","author":"P Caramaschi","year":"2007","unstructured":"Caramaschi P, Biasi D, Volpe A, Carletto A, Cecchetto M, Bambara LM (2007) Coexistence of systemic sclerosis with other autoimmune diseases. Rheumatol Int 27:407\u2013410","journal-title":"Rheumatol Int"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00296-018-4156-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4156-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-018-4156-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,10]],"date-time":"2019-09-10T19:07:29Z","timestamp":1568142449000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00296-018-4156-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,11]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["4156"],"URL":"https:\/\/doi.org\/10.1007\/s00296-018-4156-4","relation":{},"ISSN":["0172-8172","1437-160X"],"issn-type":[{"value":"0172-8172","type":"print"},{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,11]]},"assertion":[{"value":"14 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors hereby declare no personal or professional conflicts of interest regarding any aspect of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}